Consultant Jacob Frenkel's departure as Chairman of the Board of Brainstorm Cell Therapeutics Inc. was reported; the filing names no successor. As of November 6, 2026, Brainstorm Cell Therapeutics Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 28, 2026 to July 30, 2026, naming 1 appointment and 2 departures (Form 8-K, July 30, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Brainstorm Cell Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Brainstorm Cell Therapeutics Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-28 to 2026-07-30. They name 3 people, with 1 appointment and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Brainstorm Cell Therapeutics Inc. files it.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-30 | In | Chief Strategic Regulatory Officer | 8-K, 2026-07-30 | ||
| 2026-07-30 | Out | Chairman of the Board | 8-K, 2026-07-30 | ||
| 2026-07-30 | Out | Chief Medical Officer | 8-K, 2026-07-30 | ||
| 2026-05-28 | Reported | not named in the filing | 8-K, 2026-05-28 |
Selling to them or working with them? See who runs Brainstorm Cell Therapeutics Inc. now and the warning signs.
Free to see. No signup.
Watch Brainstorm Cell Therapeutics Inc.
Get an email when Brainstorm Cell Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Brainstorm Cell Therapeutics Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Brainstorm Cell Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Brainstorm Cell Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Who leads Brainstorm Cell Therapeutics Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Medical Officer: Ibrahim B. Dagher, departure reported (filed 2026-07-30). No successor is named in these filings.
- Chairman of the Board: Consultant Jacob Frenkel, departure reported (filed 2026-07-30). No successor is named in these filings.
- Chief Strategic Regulatory Officer: Peter Pitts, appointed (filed 2026-07-30).
New leaders reset buying decisions — get the Full Report on Brainstorm Cell Therapeutics Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Strategic Regulatory Officer at Brainstorm Cell Therapeutics Inc., with the record behind each one.
Find candidates like Chief Strategic Regulatory Officer at Brainstorm Cell Therapeutics Inc.Every change, in the filing's words
Appointed: Peter Pitts, Chief Strategic Regulatory Officer
On July 24, 2026, the Board of Directors (the " Board ") of Brainstorm Cell Therapeutics Inc. (the " Company ") appointed Peter Pitts, a member of the Board, as Executive Chairman of the Board and Chief Strategic Regulatory Officer.
Departing: Consultant Jacob Frenkel, Chairman of the Board
Executive Chairman Resignation and Transition to Consultant Jacob Frenkel, Ph.D., resigned as Chairman of the Board and as a director on July 24, 2026.
Departing: Ibrahim B. Dagher, Chief Medical Officer
On July 26, 2026, Ibrahim B. Dagher, MD, Executive Vice President and Chief Medical Officer of the Company, resigned from his positions with the Company, effective immediately.
- Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
- In connection with his appointment, Mr. Pitts and the Company entered into an offer letter dated July 24, 2026 (the "Offer Letter"), which provides a stock option grant to purchase 900,000 shares of the Company's common stock (the "Pitts Stock Option"), as evidenced by a Stock Option Grant Notice of the same date, and he will not be eligible to receive any base salary or cash bonus or participate in the director compensation program.
- The Pitts Stock Option generally vests with respect to one-fourth of the total shares on July 24, 2027, with the remaining shares vesting in equal monthly installments over the next three years.
- In recognition of Dr. Frenkel's prior service and significant contributions to the Company, the Board approved: (i) the acceleration of the vesting of Dr. Frenkel's outstanding stock options and restricted stock units; and (ii) an extension of the post-termination exercise period for each of Dr. Frenkel's outstanding and vested stock options until the earlier of (x) the second anniversary of the effective date of his resignation from the Board or (y) the expiration of the stated maximum term of the applicable stock option.
Reported
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
- On May 25, 2026, the Board of Directors (the "Board") of Brainstorm Cell Therapeutics Inc. (the "Company") approved an increase in the number of directors constituting the Board from seven to eight directors and appointed Peter Pitts to serve as a director of the Company, effective as of the same day, to serve until the Company's 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified.
- Mr. Pitts, age 67, has served as the President of the Center for Medicine in the Public Interest since 2004.
- Mr. Pitts has served as a Visiting Professor at the University of Paris School of Medicine since 2015.
- From 2001 through 2003, Mr. Pitts served as a member of the United States Senior Executive Service, and from 2001 through 2003, he was Associate Commissioner of the US Food & Drug Administration, where he served as senior communications and policy adviser to the Commissioner.
- Mr. Pitts has served as a member of the Council for International Organizations of Medical Sciences Expert Working Group to help advance patient involvement in the development and safe use of medicines since 2020.
- From 1997 though 2000, Mr. Pitts served as an adjunct professor at Indiana University's School of Public and Environmental Affairs.
- Mr. Pitts has over 30 years of experience in health care public policy, and is lead author of multiple peer-reviewed publications.
Tools for this story
Each opens in a new tab, filled in for Brainstorm Cell Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.